the 2700 was to monitor safety, but in reality, as the press release said, Fibrocell does it anyway, so nothing really extra to do
However, to your point, the FDA could come back and say we want a certain number of patients treated first before we persue another indication (acne scars).
I am sure we will hear something by year end, if they are in negiciations now with the FDA, but knowing Pernock probably 2012